David Dore

David Dore, Pharm.D., Ph.D.

Principal Scientist
Health Sciences
Natick
  • CV (English)
  • Contact Card

Dr. Dore is a pharmacoepidemiologist who specializes in studying the post-marketing safety and effectiveness of medical products as they are used in customary clinical practice. He has over 15 years of experience with regulated post-approval safety studies (PASS) conducted with secondary data sources (e.g., healthcare claims), and he has developed expertise in novel data linkages and supplementary data collection to address biases in these studies. Additionally, Dr. Dore specializes in the development and research applications of large electronic health records (EHR) systems, which typically include a myriad of data types from various health systems. This work has included evaluating and improving the quality of complex EHR data, conducting applied research that involves the use of free-text clinical notes and methods to address missing data, and the design of pragmatic randomized trials. Dr. Dore has been on the faculty at the Brown University School of Public Health since 2008.

CREDENTIALS & PROFESSIONAL HONORS

  • Ph.D., Epidemiology, Brown University, 2008
  • Pharm.D., University of Rhode Island, 2004

Publications

Zullo AR, Duprey MS, Smith RJ, Gutman R, Berry SD, Munshi MN, Dore DD. Effects of dipeptidyl peptidase-4 inhibitors and sulphonylureas on cognitive and physical function in nursing home residents. Diabetes Obes Metab. 2022;24(2):247-256. doi: 10.1111/dom.14573. PMID: 34647409

Zullo AR, Smith RJ, Gutman R, Kohler B, Duprey MS, Berry SD, Munshi MN, Dore DD. Comparative safety of dipeptidyl peptidase-4 inhibitors and sulfonylureas among frail older adults. J Am Geriatr Soc. 2021;69(10):2923-2930. doi: 10.1111/jgs.17371. PMID: 34291453; PMCID: PMC8497422

Funch D, Mortimer K, Ziyadeh NJ, Seeger JD, Zhou L, Ng E, Ross DS, Major-Pedersen A, Bosch-Traberg H, Gydesen H, Dore DD. Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population. Diabetes Metab Syndr Obes. 2021:14 2619–2629. doi: 10.2147/DMSO.S305496

Danilack VA, Hutcheon JA, Triche EW, Dore DD, Muri JH, Phipps MG, Savitz DA. Development and Validation of a Risk Prediction Model for Cesarean Delivery After Labor Induction. J Womens Health (Larchmt). 2020;29(5):656-669. doi: 10.1089/jwh.2019.7822. PMID: 31657668

Funch D, Mortimer K, Ziyadeh NJ, Seeger JD, Li L, Norman H, Major-Pedersen A, Bosch-Traberg H, Gydesen H, Dore DD. Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population. Diabetes Obes Metab. 2019;21(8):1837-1848. doi: 10.1111/dom.13739. PMID:30945402; PMCID: PMC6772183

Liang C, Bertoia ML, Ding Y, Clifford CR, Qiao Q, Gagne JJ, Dore DD. Exenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort study. Diabetes Obes Metab. 2019;21(4):1037-1042. doi: 10.1111/dom.13597. PMID: 30474347

Funch D, Mortimer K, Li L, Norman H, Major-Pedersen A, Olsen AH, Kaloft MS, Dore DD. Is there an Association between Liraglutide Use and Female Breast Cancer in a Real World Setting? Diabetes Metab Syndr Obes. 2018;11:791-806. doi: 10.2147/DMSO.S171503. PMID: 30538516

Zullo AR, Hersey M, Lee Y, Sharmin S, Bosco E, Daiello LA, Shah NR, Mor V, Boscardin WJ, Berard-Collins CM, Dore DD, Steinman MA. Outcomes of "diabetes-friendly" vs "diabetes unfriendly" β-blockers in older nursing home residents with diabetes after acute myocardial infarction. Diabetes Obes Metab. 2018;20(12):2724-2732. doi: 10.1111/dom.13451. PMID: 29952104

Loughlin AM, Qiao Q, Nunes AP, Ezzy SM, Yochum L, Clifford CR, Gately RV, Dore DD, Seeger JD. Effectiveness and Tolerability of Therapy With Once-Weekly Exenatide Versus Basal Insulin Among Injectable-Naive Patients With Type 2 Diabetes in a Real-World Setting in the United States. Diabetes Spectr. 2018;31(2):129-137. doi: 10.2337/ds16-0081. PMID: 29773932; PMCID: PMC5951230

Wang FT, Xue F, Ding Y, Ng E, Critchlow CW, Dore DD. Predictive values of diagnostic codes for identifying serious hypocalcemia and dermatologic adverse events among women with postmenopausal osteoporosis in a commercial health plan database. BMC Health Serv Res. 2018;18(1):263. doi:10.1186/s12913-018-3016-y. PMID: 29631582; PMCID: PMC5891890

Hoffman V, Abu-Elyazeed R, Enger C, Esposito DB, Doherty MC, Quinlan SC, Skerry K, Holick CN, Basile P, Friedland LR, Praet N, Wéry S, Willame C, Dore DD, Rosillon D. Safety study of live, oral human rotavirus vaccine: A cohort study in United States health insurance plans. Hum Vaccin Immunother. 2018;14(7):1782-1790. doi: 10.1080/21645515.2018.1450123. PMID: 29533129; PMCID: PMC6067866

Loughlin AM, Qiao Q, Nunes AP, Öhman P, Ezzy S, Yochum L, Clifford CR, Gately R, Dore DD, Seeger JD. Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States. Diabetes Obes Metab. 2018;20(4):898-909. doi: 10.1111/dom.13175. PMID: 29193561; PMCID: PMC5873410

Dore DD, Zullo AR, Mor V, Lee Y, Berry SD. Age, Sex, and Dose Effects of Nonbenzodiazepine Hypnotics on Hip Fracture in Nursing Home Residents. J Am Med Dir Assoc. 2018;19(4):328-332.e2. doi: 10.1016/j.jamda.2017.09.015. PMID: 29126858; PMCID: PMC5871542

Zullo AR, Sharmin S, Lee Y, Daiello LA, Shah NR, John Boscardin W, Dore DD, Lee SJ, Steinman MA. Secondary Prevention Medication Use After Myocardial Infarction in U.S. Nursing Home Residents. J Am Geriatr Soc. 2017;65(11):2397-2404. doi: 10.1111/jgs.15144. PMID: 29044457; PMCID: PMC5683399

Nunes AP, Loughlin AM, Qiao Q, Ezzy SM, Yochum L, Clifford CR, Gately RV, Dore DD, Seeger JD. Tolerability and Effectiveness of Exenatide Once Weekly Relative to Basal Insulin Among Type 2 Diabetes Patients of Different Races in Routine Care. Diabetes Ther. 2017;8(6):1349-1364. doi: 10.1007/s13300-017-0314-z. PMID: 28983857; PMCID: PMC5688980

Zullo AR, Dore DD, Gutman R, Mor V, Alvarez CA, Smith RJ. Metformin Safety Warnings and Diabetes Drug Prescribing Patterns for Older Nursing Home Residents. J Am Med Dir Assoc. 2017;18(10):879-884.e7. doi:10.1016/j.jamda.2017.05.020. PMID: 28676291; PMCID: PMC5612829

Nunes AP, Iglay K, Radican L, Engel SS, Yang J, Doherty MC, Dore DD. Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users. Diabetes Obes Metab. 2017;19(10):1425-1435. doi: 10.1111/dom.13000. PMID: 28497592

Funch D, Ross D, Gardstein BM, Norman HS, Sanders LA, Major-Pedersen A,Gydesen H, Dore DD. Performance of claims-based algorithms for identifying incident thyroid cancer in commercial health plan enrollees receiving antidiabetic drug therapies. BMC Health Serv Res. 2017;17(1):330. doi:10.1186/s12913-017-2259-3. PMID: 28476125; PMCID: PMC5420112

Steinman MA, Zullo AR, Lee Y, Daiello LA, Boscardin WJ, Dore DD, Gan S, Fung K, Lee SJ, Komaiko KDR, Mor V. Association of β-Blockers With Functional Outcomes, Death, and Rehospitalization in Older Nursing Home Residents After Acute Myocardial Infarction. JAMA Intern Med. 2017;177(2):254-262. doi: 10.1001/jamainternmed.2016.7701.PMID: 27942713

Nunes AP, Yang J, Radican L, Engel SS, Kurtyka K, Tunceli K, Yu S, Iglay K, Doherty MC, Dore DD. Assessing Occurrence of Hypoglycemia and its Severity from Electronic Health Records of Patients with Type 2 Diabetes Mellitus. Diabetes Res Clin Pract. 2016;121:192-203. doi: 10.1016/j.diabres.2016.09.012

Zullo AR, Lee Y, Daiello L, Dore DD, Mor V, Boscardin WJ, Miao Y, Fung K Komaiko K, Steinman MA. Beta-Blocker Use Among United States Nursing Home Residents After Myocardial Infarction: A National Study. J Am Geriatr Soc. 2017;65(4):754-762. doi: 10.1111/jgs.14671. PMID: 27861719

Fain KM, Castillo-Salgado C, Dore DD, Segal JB, Zullo AR, Alexander GC. Inappropriate Fentanyl Prescribing Among Nursing Home Residents in the United States. J Am Med Dir Assoc. 2017;18(2):138-144. doi: 10.1016/j.jamda.2016.08.015. PMID: 27720662

Fain KM, Alexander GC, Dore DD, Segal JB, Zullo AR, Castillo-Salgado C. Frequency and Predictors of Analgesic Prescribing in U.S. Nursing Home Residents with Persistent Pain. J Am Geriatr Soc. 2017;65(2):286-293. doi: 10.1111/jgs.14512. PMID: 28198563

Zullo AR, Dore DD, Gutman R, Mor V, Alvarez C, Smith RJ. National Glucose-lowering Treatment Complexity is Greater among Nursing Home Residents than Community-dwelling Adults. J Am Geriatr Soc. 2016 Nov;64(11):e233-e235. doi: 10.1111/jgs.14485. PMID: 27677102

Hoffman V, Everage NJ, Quinlan SC, Skerry K, Esposito D, Praet N, Rosillon D, Holick CN, Dore DD. Validation of current procedural terminology codes for rotavirus vaccination among infants in two commercially insured US populations. Pharmacoepidemiol Drug Saf. 2016;25(12):1465-1469. doi: 10.1002/pds.4085. PMID: 27623759

Danilack VA, Triche EW, Dore DD, Muri JH, Phipps MG, Savitz DA. Comparing expectant management and spontaneous labor approaches in studying the effect of labor induction on cesarean delivery. Ann Epidemiol. 2016 Jun;26(6):405-411.e1. doi: 10.1016/j.annepidem.2016.04.009

Genberg BL, Rogers WH, Lee Y, Qato DM, Dore DD, Hutchins DS, Brennan T, Matlin OS, Wilson IB. Prescriber and pharmacy variation in patient adherence to five medication classes measured using implementation during persistent episodes. Pharmacoepidemiol Drug Saf. 2016;25(7):790-7. doi: 10.1002/pds.4025. PMID: 27174150

Zullo AR, Dore DD, Daiello L, Baier RR, Gutman R, Gifford DR, Smith RJ. National Trends in Treatment Initiation for with Diabetes Mellitus, 2008-2010. J Am Med Dir Assoc. 2016;17(7):602-8. doi: 10.1016/j.jamda.2016.02.023

Qato DM, Trivedi A, Mor V, Dore DD. Disparities in Discontinuing Rosiglitazone Following the 2007 FDA Safety Alert. Med Care. 2016;54(4):406-13. doi: 10.1097/MLR.0000000000000502

Liang C, Seeger JD, Dore DD. Implications of immortal person-time when outcomes are nonfatal. Ann Epidemiol. 2016;26(3):212-7. doi: 10.1016/j.annepidem.2015.12.004

Lin ND, Norman H, Regev A, Perahia DG, Li H, Chang CL, Dore DD. Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a US health care claims database. BMC Gastroenterol. 2015;15:134. doi: 10.1186/s12876-015-0373-4

Danilack VA, Dore DD, Triche EW, Muri JH, Phipps MG, Savitz DA. The effect of labour induction on the risk of caesarean delivery: using propensity scores to control confounding by indication. BJOG. 2016;123(9):1521-9. doi: 10.1111/1471-0528.13682. PMID: 26411752

Joyce N, Wellenius GA, Dore DD, Newburger JW, Zachariah JP. Patterns of Lipid Lowering Therapy among Children Ages 8-20 Years. J Pediatr. 2015;167(1):113-9.e1. doi: 10.1016/j.jpeds.2015.04.004

Zullo AR, Dore DD, Galarraga O. Development and validation of an index to predict personal prescription drug importation by adults in the United States. J Pharma Health Serv Res. 2015;6(1):33-41. doi: 10.1111/jphs.12088

Cooper AL, Dore DD, Kazis LE, Mor V, Trivedi AN. Predictors of high-risk prescribing among elderly Medicare Advantage beneficiaries. Am J Manag Care. 2014;20(10):e469-78

Dore DD, Ziyadeh N, Cai B, Clifford CR, Norman H, Seeger JD. A cross-sectional study of the identification of prevalent asthma and chronic obstructive pulmonary disease among initiators of long-acting β-agonists in health insurance claims data. BMC Pulm Med. 2014;14:47. doi: 10.1186/1471-2466-14-47

Cooper AL, Kazis LE, Dore DD, Mor V, Trivedi AN. Underreporting high-risk prescribing among Medicare Advantage plans: a cross-sectional analysis. Ann Intern Med. 2013;159(7):456-62. doi: 10.7326/0003-4819-159-7-201310010-00005

Dore DD. A Day in the Life of a Corporate Retail Pharmacist. Ann Intern Med. 2013;159(5):366-7. doi: 10.7326/0003-4819-159-5-201309030-00014

Dore DD, Hussein M, Hoffman C, Pelletier EM, Smith DB, Seeger JD. A pooled analysis of exenatide use and risk of acute pancreatitis. Curr Med Res Opin. 2013;29(12):1577-86. doi: 10.1185/03007995.2013.838550

Dore DD, Swaminathan S, Gutman R, Trivedi AN, Mor V. Erythropoietin-Stimulating Agents and Survival in End-Stage Renal Disease: Comparison of Payment Policy Analysis, Instrumental Variables, and Multiple Imputation of Potential Outcomes. J Clin Epidemiol. 2013;66(8 Suppl):S42-50. doi: 10.1016/j.jclinepi.2013.02.014. PMCID: 477676

Berry SD, Lee Y, Cai S, Dore DD. Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. JAMA Intern Med. 2013;173(9):754-61. doi: 10.1001/jamainternmed.2013.3795

Dore DD, Seeger JD, Chan KA. Incidence of Health Insurance Claims for Thyroid Neoplasm and Pancreatic Malignancy in Association with Exenatide Twice Daily: Signal Refinement Using Active Safety Surveillance. Ther Adv Drug Saf. 2012;3(4):157–164. DOI: 10.1177/ 2042098612446473

Dore DD, Liang C, Ziyadeh N, Norman H, Bayliss M, Seeger JD. Linkage of Routinely Collected Oncology Clinical Data with Health Insurance Claims Data—An Example with Aromatase Inhibitors, Tamoxifen, and All-Cause Mortality. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 2:29-36. doi: 10.1002/pds.3244

Dore DD, Turnbull BR, Seeger JD. Vaccine Discontinuation and Switching Following Regulatory Interventions in Response to Rotavirus Vaccine Contamination with Porcine Circovirus DNA Fragments. Pharmacoepidemiol Drug Saf. 2012;21(4):415-9. doi: 10.1002/pds.3217

Wang S, Linkletter C, Dore D, Mor V, Buka S, Maclure M. Age, antipsychotics, and risk of ischemic stroke in the Veteran’s Health Administration (VHA). Stroke. 2012;43(1):28-31

Wang SV, Linkletter C, Maclure M, Dore DD, Mor V, Buka SL, Wellenius GA. Future cases as present controls to adjust for exposure-trend bias in case-only studies. Epidemiol. 2011;22(4):567-573

Dore DD, Bloomgren GL, Wenten M, Hoffman C, Clifford CR, Quinn SG, Braun DK, Noel RA, Seeger JD. A Cohort Study of Acute Pancreatitis in Relation to Exenatide Use. Diabetes Obes Metab. 2011;13(6):559-66. doi: 10.1111/j.1463-1326.2011.01376.x

Dore DD, Chaudhry S, Hoffman C, Seeger JD. Stratum-specific positive predictive values of claims for acute pancreatitis among commercial health insurance plan enrollees with diabetes mellitus. Pharmacoepidemiol Drug Saf. 2011;20(2):209-13. doi: 10.1002/pds.2077

Dore DD, Norman H, Loughlin J, Seeger JD. Extended Case-Control Study Results on Thromboembolic Outcomes among Transdermal Contraceptive Users. Contraception. 2010;81(5):408-413

Dore DD, Trivedi AN, Mor V, Friedman JH, Lapane KL. Atypical Antipsychotic Use and Risk of Fracture in Persons with Parkinson’s Disease. Mov Disord. 2009;24(13):1941-1948

Dore DD, Trivedi AN, Mor V, Lapane KL. Association Between Extent of Thiazolidinedione Exposure and Risk of Acute Myocardial Infarction. Pharmacotherapy. 2009;29(7):775-783

Dosa DM, Dore DD, Mor V, Teno JM. Frequency of Long-Acting Opioid Analgesic Initiation in Opioid-Naïve Nursing Home Residents. J Pain Symptom Manage. 2009;38(4):515-521

Daiello L, Ott, B, Lapane KL, Reinert S, Machan JT, Dore DD. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacother. 2009;7(2):74-83

Dore DD, Seeger JD, Chan KA. Use of a Claims-Based Active Drug Safety Surveillance System to Assess the Risk of Acute Pancreatitis with Exenatide or Sitagliptin Compared to Metformin or Glyburide. Curr Med Res Opin. 2009;25(4):1019-1027

Dore DD, Lapane KL, Trivedi AN, Mor V, Weinstock MA. Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial. Ann Intern Med. 2009;150(1):9-18

Lapane KL, Quilliam BJ, Dore DD. Roadblock on the Health IT Superhighway: E-Prescribing and the Controlled Substances Act. J Opioid Manag. 2007;3(4):181-184

Dore DD, DiBello JR, Lapane KL. Telithromycin Use and Spontaneous Reports of Hepatotoxicity. Drug Saf 2007;30(8):697-703

Caron MF, Dore DD, Min B, Kluger J, Boguk I, White CM. The Electrocardiographic and Blood Pressure Effects of the Ephedra Containing TrimSpa Thermogenic Herbal Compound in Healthy Volunteers. Pharmacotherapy 2006;26(9):1241-1246

Dore DD, Larrat EP, Vogenberg FR, Principles of Epidemiology for Clinical and Formulary Management Professionals. P & T 2006;31(4):218-229

Other Scholarly Publications

Dore DD. A day in the life of a corporate retail pharmacist (Letter in Response to Brock). Ann Intern Med. 2014;160(1):70. doi: 10.7326/L14-5000-1

Berry SD, Dore DD. Understanding drug effects in older people: the role of pharmacology-reply. JAMA Intern Med. 2013;173(20):1930-1. doi: 10.1001/jamainternmed.2013.9762

Dore DD, Norman H, Seeger JD. Eligibility Criteria in Venous Thromboembolism, Myocardial Infarction, and Stroke Among Transdermal Contraceptive System Users. Obstet Gynecol 2009;114(1):175.

Dore DD, Zierler S. Over-Reliance on Patient Information Sheets. Am J Med 2007;120(8):e3.

Presentations

(Invited Presentations, excluding abstract submissions to professional conferences)

2021. Dore DD. “Long-term Care and Geriatric Pharmacoepidemiology.” Graduate Seminar, Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research. December 8, 2021. New Brunswick, NJ (via Zoom)

Dore DD. "Large Scale Electronic Health Records Systems in Pharmacoepidemiology -Centralized Systems and Unstructured Data." Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital & Harvard Medical School. May, 2020. Boston, MA (via Zoom)

Dore DD. "Big Data and Dementia: Improving Care through Juxtaposition of Disparate Data." World Dementia Council. Tokyo, Japan. March, 2018

Dore DD. "Infrastructure for Pragmatic Trials of Dementia Care." State of the Science for Pragmatic Trials of Non-Pharmacological Interventions to Improve Outcomes Among Persons with Dementia and Their Caregivers. National Institute on Aging, Bethesda, MD. December, 2017

Dore DD. “Development and Early Applications of a Large-Scale, Physically Integrated Electronic Health Records Database for Research and Population Health Management." Department of Quantitative Health Sciences, University of Massachusetts Medical School. Worcester, MA, 2017

Dore DD (Panelist). "What Can We Learn from Real-world Data - Potential for Data Analytics." Workshop on Real-world Evidence Generation and Evaluation of Therapeutics. National Academies of Science, Engineering, and Medicine (Institute of Medicine). Washington, DC. 2016

Dore DD. "Applying Principles of Observational Research to "Big Data." Novo Nordisk, Copenhagen, Denmark. 2015

Dore DD. "Exenatide Use and Risk of Acute Pancreatitis: A Multi-component Drug Safety Assessment Program." Novo Nordisk, Copenhagen, Denmark. 2015

Dore DD, Mortimer KM. "Keeping up with "Big Data" in Clinical Development, Drug Safety, and Medical Affairs" Astellas Pharmaceuticals, Chicago, IL. 2015

Dore DD. "Research with Electronic Health Records - Epidemiologists Needed for Richer Analyses." Bristol-Myers Squibb, New Brunswick, NJ. 2015

Dore DD. "Electronic Health Records, Missing Data, and Causal Inference." Amgen Center for Observational Research, Thousand Oaks, CA. 2014

Dore DD. "Case Studies in Post-marketing Drug Safety Evaluation." Department of Epidemiology, GlaxoSmithKline, Research Triangle Park, NC. 2013

Dore DD. Getting More from Your Trial Data Through Linkage with Administrative Data — A Pharmacoepidemiologist's Perspective. Steering Committee Meeting, NIH Pelvic Floor Disorders Network Meeting, Providence, RI. 2013

Dore DD. A Case-crossover Study of Age-, Gender-, and Dose-Specific Effects on Non-benzodiazepine Hypnotics on the Occurrence of Hip Fracture in Nursing Home Residents. Seminar, Department of Epidemiology, Program in Public Health, Brown University. 2013

The Ortho Evra ® Thromboembolism Study and Supplementary Data Collection to Address Bias in Studies using Health Insurance Claims Data. Invited Seminar. Department of Obstetrics and Gynecology, Alpert Medical School/Women and Infants' Hospital. Providence RI. 2012

Dore DD. Exenatide Use and Risk of Acute Pancreatitis: A Multi-study Drug Safety Assessment Program. Invited Seminar. Department of Population Medicine, Harvard Medical School, Boston, MA. 2011

Dore DD. Exenatide Use and Risk of Acute Pancreatitis: A Multi-study Drug Safety Assessment Program. Invited Seminar. Harvard School of Public Health, Boston, MA. 2011

Dore DD. Speaker: Exploring Nontraditional Career Paths, a panel discussion for BioMed Graduate Students and Postdocs featuring PhD's working in industry, entertainment, and government. Brown University. 2011

Dore DD. Use of Commercial Health Insurance Claims Data for Studying HIV/AIDS Care. Testimony to the Institute of Medicine Committee on Data Systems for Monitoring HIV Care. Washington, DC. 2011

Anderson D, Dore DD. Ingenix Natural History of Disease Application — Uses for Pharmacoepidemiology. Seminar in Medical Bioinformatics. Stanford University Medical School, Palo Alto, CA. 2011

Dore DD. Exenatide Use and Risk of Acute Pancreatitis: A Post-marketing Drug Safety Program Involving Safety Signal Refinement, Going Beyond Claims Data, and Mitigating Misclassification Bias and Confounding in a Distributed Data Model. Seminar, Section of Health Services, Policy, and Practice, Department of Community Health, Brown University, Providence, RI. 2011

Prior Experience

Epidemiologist, Vice President, Chief Research Officer, Optum/UnitedHealth Group, 2007 – 2019

Assistant Professor of Health Services, Policy & Practice (tenure track) and Assistant Professor of Epidemiology, Brown University of School of Public Health, 2011 – 2014

Academic Appointments

Adjunct Professor of Health Services, Policy & Practice, Brown University School of Public Health, 2022 - Present

Adjunct Assistant Professor of Health Services, Policy & Practice, Brown University School of Public Health, 2008 - 2022

Professional Affiliations

International Society for Pharmacoepidemiology

International Society for Pharmacoeconomics and Outcomes Research

Project Experience

Technical & Data Lead, Long Term Care Data Cooperative. Funded by the National Institute on Aging via Brown University School of Public Health. Principal Investigator: Vincent Mor, Ph.D.

Additional Information

Advisory Appointments

Member, Point-of-care Trials Workgroup. Duke-Margolis Center for Health Policy. (Appointed representative of the International Society for Pharmacoepidemiology.) 2022 – Present

Member, Expert Advisory Panel, “Observational Patient Evidence for Regulatory Approval and uNderstanding Disease (OPERAND).” Led by OptumLabs & The Multi-regional Clinical Trials Center (MRCT) of Brigham and Women’s Hospital and Harvard University. 2018 – Present

Member, North American Regional Advisory Committee, Drug Information Association. 2017 – 2020

Workgroup Member, “State of the Science for Pragmatic Trials of Non-Pharmacological Interventions to Improve Outcomes Among Persons with Dementia and Their Caregivers.” National Institute on Aging, Bethesda, MD. 2017

Panelist, “Real-World Evidence Generation and Evaluation of Therapeutics: A Workshop.” The National Academy of Sciences, Engineering, and Medicine (Institute of Medicine). Washington, DC. 2016

Workgroup Member, “Data Quality and Missing Data in Patient-Centered Outcomes Research Using EMR/Claims Data.” Patient-centered Outcomes Research Institute (PCORI). Washington, DC. 2015

Peer Reviewer

Journal of the American Medical Association (JAMA)

PLOS One

Current Medical Research and Opinion

Medical Care

American Journal of Epidemiology

British Medical Journal (BMJ)

Journal of Clinical Epidemiology

Effective Health Care Program of the Agency for Healthcare Research and Quality (AHRQ)

Medicare & Medicaid Research Review

Epidemiology

Diabetes, Obesity, and Metabolism

Diabetologia

Journal of the European Academy of Dermatology and Venereology

Pharmacoepidemiology and Drug Safety

FDA Mini-Sentinel Project

Annals of Internal Medicine

JAMA Internal Medicine (Archives of Internal Medicine)

Diabetes Research and Clinical Practice

Journal of Diabetes Science and Technology

Movement Disorders

Clinical Therapeutics

Journal of Managed Care Pharmacy

American Journal of Geriatric Pharmacotherapy

Annals of Pharmacotherapy

Journal of Pharmacy Technology

News & Events